Program
YN001
A development code. Also written as “YN001, Rosuvastatin calcium Tablets”, “Dose 1 YN001” and “Dose 2 YN001”.
Its studies are mostly in Atherosclerosis · Coronary Artery Disease · Cerebrovascular Disorders · Cardiovascular Diseases, led by Beijing Inno Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Inno Medicine | 61 open or running | phase 2since Sep 16, 2023 | Oct 20, 2022 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 20, 2022First study: phase 1 study in Cardiovascular DiseasesFirst studyNCT05635084 · 64 enrolled · Australia
- Sep 16, 2023Phase 2 study in AtherosclerosisNCT06048588 · 144 enrolled · China
- Nov 14, 2024Phase 2 study in Coronary Artery DiseaseNCT06700720 · 3 enrolled · Australia
- Sep 17, 2025Phase 1 study in Healthy VolunteersNCT07190885 · 24 enrolled · Australia
- Nov 19, 2025Phase 2 study in AtherosclerosisNCT07311330 · 40 planned · China
- Nov 27, 2025Phase 1 study in Cerebrovascular DisordersNCT07309042 · 24 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07309042Cerebrovascular Disorders · China | 1 | Completed | Mar 30, 2026 | 24 |
| NCT07311330Atherosclerosis · China | 2 | Recruiting | Oct 2026 | 40 |
| NCT07190885Healthy Volunteers · Australia | 1 | Suspended | Sep 2026 | 24 |
| NCT06700720Coronary Artery Disease · Australia | 2 | Terminated | Jul 22, 2026 | 3 |
| NCT06048588Atherosclerosis · China | 2 | Completed | Apr 27, 2025 | 144 |
| NCT05635084Cardiovascular Diseases · Australia | 1 | Completed | Aug 9, 2024 | 64 |
How it is read
Names in the registry
- “YN001, Rosuvastatin calcium Tablets”, 3 entries
- “YN001”, 3 entries
- “Dose 1 YN001”, 1 entry
- “Dose 2 YN001”, 1 entry
- “YN001 20mg Dose + 5% glucose injection”, 1 entry
Codes read as this program: YN001.
Conditions, from the studies’ own filings
- Atherosclerosis, 2 studies
- Coronary Artery Disease, 1 study
- Cerebrovascular Disorders, 1 study
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.